Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $85.37, for a total transaction of $631,738.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Elena Ridloff also recently made the following trade(s):

• On Wednesday, April 1st, Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock. The stock was sold at an average price of $85.42, for a total transaction of $392,932.00.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $85.40 on Friday. The stock has a fifty day simple moving average of $81.57 and a two-hundred day simple moving average of $72.16. The firm has a market capitalization of $6.97 billion, a PE ratio of -23.21 and a beta of 2.28. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. Kymera Therapeutics’s revenue was down 60.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.88) earnings per share. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP increased its stake in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after acquiring an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, BVF Inc. IL increased its position in Kymera Therapeutics by 6.6% in the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after purchasing an additional 340,909 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have weighed in on KYMR shares. HC Wainwright upped their price target on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. UBS Group lifted their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Wells Fargo & Company boosted their target price on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Citigroup upped their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Piper Sandler raised their target price on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $118.90.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Multiple research firms have raised price targets and reiterated buy/outperform views (Mizuho, Oppenheimer, B. Riley, Leerink, UBS), supporting upside expectations for KYMR. Analyst Upgrades and Targets
• Positive Sentiment: Large institutional holders (Baker Bros., Avoro, Vanguard, Price T. Rowe, BVF) increased positions in recent quarters, signaling continued fund-level conviction in Kymera’s Pegasus degrader platform and pipeline. Institutional Activity
• Neutral Sentiment: Company fundamentals/context: Kymera is a clinical‑stage degrader-focused biotech with a mixed near‑term financial picture (recent quarter missed revenue and EPS estimates). These operational results remain a material background factor for how investors value upcoming clinical and partnership milestones. Earnings and Company Profile
• Negative Sentiment: Director Elena Ridloff sold 4,600 shares on April 1 at an average price of ~$85.42 (disclosed via SEC). Large director sales can create near-term selling pressure or signal personal liquidity needs. Ridloff sale (AmericanBankingNews)
• Negative Sentiment: Additional disclosures show Ridloff sold 7,400 shares on March 31 and the April 1 sale was also filed with the SEC. Total recent Ridloff sales amount to ~12,000 shares across the two trades. Ridloff SEC filing
• Negative Sentiment: COO Jeremy G. Chadwick disclosed multiple sales (7,600 on March 31 and 14,640 on April 1) totaling ~22,240 shares at ~\$85.4 average — a roughly double‑digit percentage reduction in his reported ownership. Senior‑exec selling of this size can weigh on sentiment. Chadwick SEC filing
• Negative Sentiment: Multiple independent reports aggregated these insider trades (InsiderTrades, MarketBeat), increasing transparency but also spotlighting the concentration of recent insider liquidity. InsiderTrades summary

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.